Ben Pfeifer

Aeskulap International is a Swiss-based healthcare and research organization specializing in integrative oncology, founded by Prof. Dr. Ben Pfeifer. The company is primarily recognized for the development and clinical application of the Pfeifer Protocol, an integrative treatment strategy for hormone-refractory prostate cancer. This protocol utilizes a synergistic combination of botanical extracts and targeted supplements to manage disease progression and improve patient quality of life. Aeskulap International operates clinical facilities that provide personalized cancer care, focusing on the intersection of conventional oncology and evidence-based complementary medicine. The organization also engages in clinical research to validate the efficacy of phytotherapeutic agents in cancer management.